The incidence of this life-threatening acute-on-chronic liver failure (ACLF) is increasing, and early detection and cure are urgent clinical needs. Pillar III applies a Systems Medicine approach to identify the critical mechanisms of acute-on-chronic liver failure (ACLF) and to foster liver regeneration and repair.
- People (35)
- Institutions (15)
- Investigations (1)
- Studies (0+1)
- Assays (0+2)
- Data files (2+26)
- SOPs (3)
- Publications (28)
- Presentations (11+18)
- Events (5+3)
- Documents (1+90)
Roles: Project Coordinator
Projects: Chronic Liver Disease Progression (LiSyM-DP - Pillar II), Early Metabolic Injury (LiSyM-EMI - Pillar I), LiSyM Core Infrastructure and Management (LiSyM-PD), LiSyM network, LiSyM Scientific Leadership Team, Liver Function Diagnostics (LiSyM-LiFuDi - Pillar IV), Model Guided Pharmacotherapy In Chronic Liver Disease (LiSyM-MGP), Molecular Steatosis - Imaging & Modeling (LiSyM-MSIM), Multi-Scale Models for Personalized Liver Function Tests (LiSyM-MM-PLF), Project Management PTJ, Regeneration and Repair in Acute-on-Chronic Liver Failure (LiSyM-ACLF - Pillar III), The Hedgehog Signalling Pathway (LiSyM-JGMMS)
Institutions: LiSyM programme directorate
Date Published: 30th Jul 2019
Journal: Sci Rep
PubMed ID: 31363109
Citation: Sci Rep. 2019 Jul 30;9(1):11021. doi: 10.1038/s41598-019-46791-8.
Authors: T Lin, S Wang, C Shao, X Yuan, F Wandrer, H Bantel, MP Ebert, H Ding, Steven Dooley, HL Weng
Date Published: 2019
Journal: Not specified
Citation: 35. Jahrestagung der Deutschen Arbeitsgemeinschaft zum Studium der Leber,Georg Thieme Verlag KG.2019
Date Published: 1st Feb 2019
Journal: Clin Transl Gastroenterol
PubMed ID: 30702490
Citation: Clin Transl Gastroenterol. 2019 Jan;10(1):e00002. doi: 10.14309/ctg.0000000000000002.
The meeting will provide a great opportunity for discussion between modellers, experimentalists and clinicians and to organize and harmonize our future work within the LiSyM network on the grassroot level.
Start Date: 20th Nov 2017
End Date: 22nd Nov 2017
Event Website: Not specified
The International Conference on Systems Biology of Human Disease (SBHD) is a transatlantic event and communication platform for scientific exchange that takes place alternately between the United States and Germany.
SBHD 2017 is continuing a conference series launched by Peter Sorger and colleagues from Harvard Medical School in 2008. The conference focus is on mammalian systems biology, particularly on its application to human disease and therapy.
This summit will cover both the basic and translational / clinical aspects of NAFLD, with a specific focus on novel drug target and prognostic signature development.
Key sessions include all crucial pathophysiological aspects currently known to affect development and progression of NAFLD, such as "lipid metabolism and lipotoxicity" and "insulin resistance, insulin and hormonal signaling". Furthermore, oxidative stress, ER stress, and mitochondrial dysfunction will be addressed. On the second day,
Start Date: 9th Nov 2017
End Date: 11th Nov 2017
ICSB continues to be the flagship conference of the International Society for Systems Biology (ISSB). The conference will cover a variety of themes from Fundamental Biological Sciences, Network Analysis, to Metabolic Engineering and Cancer Biology. The conference will also include a variety of engaging plenary lectures, parallel sessions, poster sessions, and interactive networking opportunities.
Abstract submission deadline: May 13th, 2017
This event is a jointly organized Data Management PALs Meeting that involves PALs from the German LiSyM (Liver Systems Medicine) network and from the ERASysAPP (ERA-Net for Systems Biology Applications) initiative. PALs (Project Area Liaisons) are the front line experts of the data management teams of these projects. They act as data management advocates and help gathering user requirements and testing potential data management solutions. An important part of the meeting will be to gather the
Non-alcoholic fatty liver disease and nonalcoholic
steatohepatitis can lead to
advanced liver disease. Both conditions
are becoming increasingly prevalent as
the epidemics of obesity and diabetes
continue to increase. A mathematical
model was built to understand how the
disease burden associated with nonalcoholic
fatty liver disease and nonalcoholic
steatohepatitis will change over
time. Results suggest increasing cases of
advanced liver disease and liver-related
mortality in the coming years.
Contributor: Ina Schmitt
Investigations: LiSyM Pillar III: Regeneration and Repair in Ac...
Studies: 1 hidden item
Assays: 1 hidden item